Navigation Links
Thrombosis Experts Present Update on Important New Developments in Anticoagulation Management

RESEARCH TRIANGLE PARK, N.C., Oct. 29 /PRNewswire/ -- Pharmaceutical Strategic Initiatives® announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.  The symposium titled Anticoagulation Management at the Crossroads –Addressing the Developments Impacting Future Decades was sponsored by Research Triangle Park, NC based Pharmaceutical Strategic Initiatives, LLC.  This interactive symposium was organized in collaboration with the Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, the North American Thrombosis Forum (NATF), and the International Union of Angiology (IUA).

Professor Jawed Fareed, Ph.D., Professor of Pathology and Pharmacology, Director of Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, was the chair for the program which also included presentations regarding emerging topics in anticoagulation management and for patients at risk of thrombosis and related disorders.  The distinguished faculty representing leading international institutions included Professor Samuel Goldhaber, MD from Brigham and Women's Hospital in Boston, MA, Professor Jeanine Walenga, Ph.D. from Loyola University Medical Center in Maywood, IL, Professor Benjamin Brenner from Rambam Health Care Campus in Haifa, Israel, Massimo Iacobelli, M.D. from Gentium, S.P.A. in Como Italy, Professor Selim Corbacioglu, M.D. from Children's Hospital Regensburg in Regensburg, Germany, Ilene Sussman, Ph.D. from the North American Thrombosis Forum in Boston, MA and Charles Carter, Pharm.D. from Pharmaceutical Strategic Initiatives, LLC in Research Triangle Park, NC.  The topics presented and discussed covered new treatment modalities for the prevention and treatment of patients at risk for thrombotic and vascular disorders including atrial fibrillation, acute coronary syndromes, diabetes, cancer and transplantation associated venous occlusive disorder.  In addition, the panel considered recent worldwide regulatory developments that are changing the landscape of anticoagulation therapy which includes the introduction of newer oral anticoagulants and generic versions of branded drugs.  The symposium was very well attended and a number of the hematology professionals who attended expressed their appreciation of this timely and informative session.

Pharmaceutical Strategic Initiatives LLC (PSI) is the premier provider of strategic clinical and regulatory consulting, priority comparative effectiveness and outcomes research, scientific content creation, opinion leader development and management to Academic Institutions, Pharmaceutical, Medical Device and Biotechnology companies. For 26 years, PSI has supported Educational Programs and Workshops, Medical Affairs, Regulatory Affairs, and Medical Marketing teams by developing successful business strategies and providing the implementation skills required to produce clear, measurable outcomes.  Charles A. Carter, Pharm.D., MBA is president of Pharmaceutical Strategic Initiatives, LLC.  PSI's offices are in Research Triangle Park, North Carolina.

SOURCE Pharmaceutical Strategic Initiatives LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
3. The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment
4. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
5. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
6. Nanobiotechnology experts join forces to improve TB testing
7. Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics
8. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. What's Next for Stevia? Experts from GLG Life Tech Corp Share Views on Stevia's Future at Complimentary Webinar on 17 Feb.
11. Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
Breaking Biology News(10 mins):